← Leaderboards
Shinichiro Kurosawa
Oklahoma Medical Research Foundation
$10,924,747
Attributed
$10,924,747
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–16$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$10,924,747 · 7
By mechanism
R01$5,164,272 · 3
U01$3,689,028 · 1
U19$2,003,330 · 2
M01$68,117 · 1
Top collaborators
No co-investigators on record.
Most similar at Oklahoma Medical Research Foundation
Same institution · by research overlap
- Judith A James$55,525,870
- Robert A Floyd$2,690,544
- Deborah J Stearns-Kurosawa$1,350,614
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionBacteriaBaseToxinSeverity Of IllnessAnimal ModelNonhuman PrimatePapioPre-ClinicalPharmaceutical PreparationsOrganResearch PersonnelMortality Vital StatisticsResponseInfusion ProceduresAntibioticsPathogenDoseClinically RelevantMorbidity - Disease RateSeptic ToxemiaMolecularBasic ScienceCessation Of Life
Grant awards (25)
Development and Treatment of Pre-Clinical EHEC Models with HUS$409,250
R01 · FY2016 · AI · contact PI
Development and Treatment of Pre-Clinical EHEC Models with HUS$409,250
R01 · FY2015 · AI · contact PI
Development and Treatment of Pre-Clinical EHEC Models with HUS$409,250
R01 · FY2014 · AI · contact PI
Translation of immunologic technologies from basic research into pre-clinical non$401,460
U19 · FY2013 · AI · contact PI
Development and Treatment of Pre-Clinical EHEC Models with HUS$384,695
R01 · FY2013 · AI · contact PI
Translation of immunologic technologies from basic research into pre-clinical non$401,462
U19 · FY2012 · AI · contact PI
SHIGA-TOXINS: PRE-CLINICAL ANIMAL MODEL DEVELOPMENT AND THERAPEUTIC TESTING$653,422
U01 · FY2011 · AI · contact PI
Translation of immunologic technologies from basic research into pre-clinical non$387,741
U19 · FY2011 · AI · contact PI
SHIGA-TOXINS: PRE-CLINICAL ANIMAL MODEL DEVELOPMENT AND THERAPEUTIC TESTING$783,314
U01 · FY2010 · AI · contact PI
Translation of immunologic technologies from basic research into pre-clinical non$408,317
U19 · FY2010 · AI · contact PI
SHIGA-TOXINS: PRE-CLINICAL ANIMAL MODEL DEVELOPMENT AND THERAPEUTIC TESTING$765,059
U01 · FY2009 · AI · contact PI
PRIMATE MODEL AND PATHOGENESIS OF ANTHRAX SEPSIS$485,739
R01 · FY2009 · AI · contact PI
Translation of immunologic technologies from basic research into pre-clinical non$404,350
U19 · FY2009 · AI · contact PI
SHIGA-TOXINS: PRE-CLINICAL ANIMAL MODEL DEVELOPMENT AND THERAPEUTIC TESTING$754,666
U01 · FY2008 · AI · contact PI
PRIMATE MODEL AND PATHOGENESIS OF ANTHRAX SEPSIS$487,215
R01 · FY2008 · AI · contact PI
SHIGA-TOXINS: PRE-CLINICAL ANIMAL MODEL DEVELOPMENT AND THERAPEUTIC TESTING$732,567
U01 · FY2007 · AI · contact PI
PRIMATE MODEL AND PATHOGENESIS OF ANTHRAX SEPSIS$476,212
R01 · FY2007 · AI · contact PI
PRIMATE MODEL AND PATHOGENESIS OF ANTHRAX SEPSIS$476,264
R01 · FY2006 · AI · contact PI
PRIMATE MODEL AND PATHOGENESIS OF ANTHRAX SEPSIS$495,897
R01 · FY2005 · AI
PLASMA SEPCR LEVELS IN PATIENTS AFTER MYOCARDIAL INFARCTION$2,062
M01 · FY2005 · RR
Plasma sEPCR Levels in Patients After Myocardial Infarction$66,055
M01 · FY2004 · RR
THE PROTEIN C RECEPTOR AND WEGENER'S VASCULOPATHY$282,625
R01 · FY2003 · HL
THE PROTEIN C RECEPTOR AND WEGENER'S VASCULOPATHY$282,625
R01 · FY2002 · HL
THE PROTEIN C RECEPTOR AND WEGENER'S VASCULOPATHY$282,625
R01 · FY2001 · HL
THE PROTEIN C RECEPTOR AND WEGENER'S VASCULOPATHY$282,625
R01 · FY2000 · HL